Two specific groups of COVID-19 patients are recommended to be treated with a combination of two antibodies (casilibimab and imdebimab). Who International Expert and Patient Guidelines Development Group (GDG) Panel BMJ..
The first is patients with non-severe COVID-19 who are at the highest risk of hospitalization, and the second is severe or severe COVID who are seronegative, that is, they have not initiated their own antibody response to COVID-19. -19 patients.
Although the initial recommendations are based on new evidence from three trials that have not yet been peer-reviewed, Casilibimab and Indevimab are hospitalized for patients at highest risk of serious illness, such as unvaccinated and the elderly. It indicates that it probably reduces the duration of risk and symptoms. Or immunosuppressed patients.
The second recommendation is that casilibimab and imdebimab probably reduce mortality (49 less per 1000 in critically ill patients and 87 less in critically ill patients) and show the need for ventilators in seronegative patients in the RECOVERY trial. Based on data. For all other COVID-19 patients, the benefits of this antibody treatment may be meaningless.
Casilibimab and imdebimab are monoclonal antibodies that, when used together, bind to the SARS-CoV-2 peplomer and neutralize the virus’s ability to infect cells.
Recommendations are part of a living guideline developed by the World Health Organization with the methodological support of the MAGIC Evidence Ecosystem Foundation, providing up-to-date and reliable guidance on the management of COVID-19, and better willingness for physicians. We will help you make decisions. Patience.
Living guidelines allow researchers to update a summary of previously scrutinized and peer-reviewed evidence as new information becomes available.
The panel acknowledged the impact of some costs and resources associated with this treatment. This can make access to low and middle income countries difficult. For example, identifying critically ill qualified patients requires rapid serological testing, intravenous treatment using specialized equipment, and patient monitoring for allergic reactions. ..
They are also aware of the potential for new mutants to emerge that may be less effective with Casilibimab and Imdebimab antibodies.
However, given the proven benefits to patients, “recommendations should provide stimuli involved in all possible mechanisms to improve global access to interventions and related tests.” It states.
This guidance is in addition to previous recommendations for the use of interleukin-6 receptor blockers and systemic corticosteroids in patients with severe or severe COVID-19. We oppose the use of ivermectin and hydroxychloroquine in patients with COVID-19, regardless of the severity of the disease.
WHO recommends antibody treatment for COVID-19 patients at high risk of hospital admission Source link WHO recommends antibody treatment for COVID-19 patients at high risk of hospital admission